G
Guido Lucarelli
Researcher at University of Rome Tor Vergata
Publications - 133
Citations - 6666
Guido Lucarelli is an academic researcher from University of Rome Tor Vergata. The author has contributed to research in topics: Transplantation & Thalassemia. The author has an hindex of 41, co-authored 133 publications receiving 6313 citations.
Papers
More filters
Journal ArticleDOI
Bone Marrow Transplantation in Patients with Thalassemia
Guido Lucarelli,Maria Galimberti,Paola Polchi,Emanuele Angelucci,Donatella Baronciani,Claudio Giardini,Politi P,Durazzi Sm,Muretto P,F. Albertini +9 more
TL;DR: It is concluded that for patients under 16 years of age, transplantation of bone marrow from an HLA-identical donor offers a high probability of complication-free survival, particularly if they do not have hepatomegaly or portal fibrosis.
Journal ArticleDOI
Hepatic Iron Concentration and Total Body Iron Stores in Thalassemia Major
Emanuele Angelucci,Gary M. Brittenham,Christine E. McLaren,Marta Ripalti,Donatella Baronciani,Claudio Giardini,Maria Galimberti,Paola Polchi,Guido Lucarelli +8 more
TL;DR: The hepatic iron concentration is a reliable indicator of total body iron stores in patients with thalassemia major and in patientsWith transfusion-related iron overload, repeated determinations of the hepaticIron concentration can provide a quantitative means of measuring the long-term iron balance.
Journal ArticleDOI
Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation
Emanuele Angelucci,Muretto P,Antonio Nicolucci,Donatella Baronciani,Buket Erer,Javid Gaziev,Marta Ripalti,Pietro Sodani,Silvia Tomassoni,Giuseppe Visani,Guido Lucarelli +10 more
TL;DR: In this article, the role of iron overload in the natural history of liver fibrosis was identified, and the risk for fibrosis progression correlated to medium hepatic iron content (hazard rate, 1.9; 95% confidence interval [CI], 0.74-5.5).
Journal ArticleDOI
Marrow transplantation for thalassaemia following busulphan and cyclophosphamide.
Guido Lucarelli,Paola Polchi,M Galimberti,T Izzi,C Delfini,M Manna,F Agostinelli,Donatella Baronciani,C. Giorgi,Emanuele Angelucci +9 more
TL;DR: 30 patients with homozygous beta-thalassaemia received allogeneic marrow transplants following busulphan (Bu) and cyclophosphamide (Cy) and post-transplant immunosuppression was with methotrexate (MTX) or MTX and Cy.
Journal ArticleDOI
Marrow Transplantation in Patients with Thalassemia Responsive to Iron Chelation Therapy
Guido Lucarelli,Maria Galimberti,Paola Polchi,Emanuele Angelucci,Donatella Baronciani,Claudio Giardini,Marco Andreani,F Agostinelli,F. Albertini,Reginald A. Clift +9 more
TL;DR: The high probability of cure with little early or late morbidity and mortality suggests that patients with class 1 thalassemia who have HLA-identical donors available should be treated by bone marrow transplantation.